Structure, function, signaling pathways and clinical therapeutics: The translational potential of STAT3 as a target for cancer therapy
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer,
Год журнала:
2024,
Номер
1879(6), С. 189207 - 189207
Опубликована: Ноя. 1, 2024
Язык: Английский
siRNA tackles cancer: Immune checkpoint inhibitors and siRNA combinations
Molecular Therapy — Nucleic Acids,
Год журнала:
2025,
Номер
36(1), С. 102429 - 102429
Опубликована: Янв. 6, 2025
Язык: Английский
Lipid-siRNA Conjugates Targeting High PD-L1 Expression as Potential Novel Immune Checkpoint Inhibitors
Biomolecules,
Год журнала:
2025,
Номер
15(2), С. 293 - 293
Опубликована: Фев. 15, 2025
Programmed
death
1
ligand
(PD-L1),
an
important
immune
checkpoint
molecule,
is
mainly
expressed
on
cancer
cells
and
has
been
shown
to
exert
immunosuppressive
effect
T-cell
function
by
binding
programmed
cell
(PD-1)
T-cells.
Recently,
inhibitors
using
antibody
drugs
such
as
nivolumab
atezolizumab
have
attracted
attention.
However,
clinical
challenges,
including
limitations
the
scope
of
their
application,
are
yet
be
addressed.
In
this
study,
we
developed
a
novel
inhibitor
that
targets
PD-L1
lipid-siRNA
conjugates
(lipid-siPDL1s).
The
inhibitory
lipid-siPDL1s
expression
was
evaluated
found
strongly
suppress
mRNA
expression.
Notably,
exerted
significantly
stronger
than
unmodified
siPDL1.
Interestingly,
inhibited
despite
stimulation
interferon-gamma,
which
induced
overexpression
genes.
These
results
suggest
could
used
inhibitors.
Язык: Английский
G0S2 Promotes PD-L1 Expression in Monocytes and Influences the Efficacy of PD-1 Inhibitors in Hepatocellular Carcinoma
Genes,
Год журнала:
2025,
Номер
16(4), С. 448 - 448
Опубликована: Апрель 13, 2025
Background:
Hepatocellular
carcinoma
(HCC)
is
a
prevalent
and
highly
lethal
form
of
liver
cancer,
with
limited
effective
treatment
options,
particularly
in
the
advanced
stages.
Immunotherapy
using
PD-1
inhibitors
has
emerged
as
promising
modality,
yet
substantial
proportion
patients
exhibit
resistance
or
fail
to
respond
such
therapies.
This
study
aimed
elucidate
role
G0/G1
Switch
2
(G0S2)
regulating
PD-L1
expression
monocytes
within
HCC
tumor
microenvironment
investigate
its
impact
on
efficacy
inhibitors.
Methods:
Gene
data
among
treated
were
obtained
from
single-cell
sequencing
database;
immunohistochemistry
was
performed
detect
G0S2
cancer
tissues
adjacent
non-tumorous
patients;
flow
cytometry
utilized
analyze
G0S2,
PD-L1,
CD206,
CD14
PBMCs
CD8+T
cell
proliferation
IFN-γ
secretion
used
evaluate
knockdown.
Results:
Utilizing
patients,
we
identified
that
significantly
elevated
non-responders
(NR)
compared
responders
(R)
inhibitor
therapy.
The
immunohistochemical
analysis
confirmed
higher
levels
tissues,
while
revealed
increased
CD206
peripheral
blood
mononuclear
cells
(PBMCs)
NR
R
healthy
controls.
functional
experiments
involving
knockdown
THP-1
monocyte
line
resulted
significant
reduction
concomitant
increase
production.
Conclusions:
These
findings
indicate
facilitates
upregulation
monocytes,
thereby
suppressing
T
activity
contributing
against
HCC.
high
offers
non-invasive
easily
detectable
biomarker
for
predicting
Consequently,
targeting
may
enhance
responsiveness
immunotherapy
providing
new
avenue
optimizing
strategies
improving
patient
outcomes.
Язык: Английский
Local CpG-Stat3 siRNA treatment improves antitumor effects of immune checkpoint inhibitors
Molecular Therapy — Nucleic Acids,
Год журнала:
2024,
Номер
35(4), С. 102357 - 102357
Опубликована: Окт. 9, 2024
Язык: Английский
Sequentially Activated Smart DNA Nanospheres for Photoimmunotherapy and Immune Checkpoint Blockade
Advanced Science,
Год журнала:
2024,
Номер
unknown
Опубликована: Ноя. 26, 2024
Abstract
Due
to
the
inherent
immunosuppression
and
immune
evasion
of
cancer
cells,
combining
photoimmunotherapy
with
checkpoint
blockade
leverages
phototherapy
enhancement,
overcoming
mutual
limitations
demonstrating
significant
anticancer
potential.
The
main
challenges
include
nonspecific
accumulation
agents,
uncontrolled
activation,
drug
carrier
safety.
Smart
DNA
nanospheres
(NS)
is
developed
targeted
delivery
controllable
release
photosensitizers
agents
achieve
effective
synergistic
therapy
minimize
side
effects.
multifunctional
NS
incorporate
a
targeting
module
for
programming
aptamers,
response
i‐motif
DNA/RNA
hybrid
sequences,
therapeutic
packaging
PD‐L1
siRNA.
navigate
tumor
site
are
sequentially
activated
by
intracellular
acid
enzymes
programmed
death
ligand
1
(PD‐L1)
small
interfering
RNA
(siRNA).
Besides
killing
promotion,
downregulate
expression,
alleviating
tolerance
evasion,
thus
enhancing
response.
These
results
indicate
that
significantly
enhance
antitumor
responses,
synergistically
improve
efficacy,
reduce
systemic
toxicity.
This
study
broadens
application
nanomaterials
in
precision
therapy.
Язык: Английский